---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029662"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:19:53.791599+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead

## Summary
- Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.
- Byron Robinson, Ph.D., Chief Strategy Officer, appointed interim head of clinical activities and team.
- Robinson assumes leadership immediately; company emphasizes experienced clinical team remains in place.

## SEC filing metadata
- accession: 0000950170-23-029662
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/janx-20230621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029662
- JSON: https://secwatch.observer/filing/0000950170-23-029662.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029662.txt

## Key facts
- Executive change
  Wayne Godfrey resigned as Chief Medical Officer at Janux Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm
- Executive change
  Byron Robinson was appointed as interim head of clinical activities at Janux Therapeutics, Inc..
  - Action: will take over
  - Role: interim head of clinical activities
  source text: On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017023029662/0000950170-23-029662-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.